A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-02-18
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).